Supplementary Figures from Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors

<p>Supplementary Figure 1. Basic functional characterization of B10G5 antibody. Supplementary Figure 2. Changes in serum levels of cytokines and chemokines with depletion of lymphocyte subsets during B10G5 therapy. Supplementary Figure 3. Anti-sMIC mAb B10G5 therapy significantly increase homeostatic proliferation of adoptively transferred NK cells. Supplementary Figure 4. B10G5 therapy did not impact CD4 T cell homeostasis but increased T-bet expression. Supplementary Figure S5. Undetectable endogenous SV40TAg epitope I-specific CD8 T cells shown by lack of positive staining by H-2Db-restrcited TAg epitope I-specific tetramer (Db/I-Tetramer). Supplementary Figure 6. Anti-sMIC mAb B10G5 therapy inhibits the growth of transplantable TRAMP-sMICB tumors. Supplementary Figure 7. Anti-sMIC therapy enhanced antigen-specific CD8 T cell responses in the transplantable TRAMP-C2-sMICB-OVA tumor model. Supplementary Figure 8. Therapeutic effect of B10G5 against well-differentiated TRAMP/MICB tumors. Supplementary Figure S9. Representative flow cytometry analyses demonstrating that depletion of NK cells during B10G5 therapy impairs CD4 T cell Th1 responses.</p>